FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999900189> ?p ?o ?g. }

• W1999900189 endingPage "645" @default.
• W1999900189 startingPage "641" @default.
• W1999900189 abstract "No AccessJournal of UrologyAdult urology1 Aug 2006Therapeutic Effect of Multiple Resiniferatoxin Intravesical Instillations in Patients With Refractory Detrusor Overactivity: A Randomized, Double-Blind, Placebo Controlled Studyis accompanied byTransient Receptor Potential Vanilloid Receptor Subtype 1 in Painful Bladder Syndrome and its Correlation With Pain Hann-Chorng Kuo, Hsin-Tzu Liu, and Wen-Chin Yang Hann-Chorng KuoHann-Chorng Kuo More articles by this author , Hsin-Tzu LiuHsin-Tzu Liu More articles by this author , and Wen-Chin YangWen-Chin Yang Departments of Urology and Pharmacy, Buddhist Tzu Chi General Hospital and Buddhist Tzu Chi University School of Medicine, Hualien, Taiwan, Republic of China More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2006.03.087AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Previous study has shown that multiple intravesical instillations of resiniferatoxin (Sigma®) at 10 nM has therapeutic effects in patients with detrusor overactivity. To our knowledge the placebo effect of multiple instillations of low dose resiniferatoxin for neurogenic and nonneurogenic detrusor overactivity has not been investigated. In this randomized, double-blind, placebo controlled study we evaluated the therapeutic effects of this resiniferatoxin treatment. Materials and Methods: A total of 54 patients with detrusor overactivity refractory to anticholinergics were enrolled and randomly treated with 4 weekly intravesical instillations of 10 nM resiniferatoxin (26) or vehicle, consisting of 10% ethanol in normal saline, as the control group (28). The clinical effects of treatment on incontinence grade, incontinence episodes, general satisfaction, lower urinary tract symptoms and urodynamic parameters were assessed. Results: Three months after completing the 4 intravesical treatments the resiniferatoxin treatment group had a significantly higher percent of patients with excellent and improved results compared to the control group (19.2% vs 7.1% and 42.3% vs 14.2%, respectively, each p <0.001). Treatment remained effective at 6 months in 13 patients (50%) in the resiniferatoxin group but in only 3 (11%) in the control group (p <0.001). Bladder capacity was significantly increased and symptom scores significantly improved 3 months after treatment in the resiniferatoxin group but not in the control group. Conclusions: Multiple intravesical instillations of 10 nM resiniferatoxin were effective for improving the incontinence grade in 62% of patients at 3 months, of whom 50% maintained a therapeutic effect 6 months after treatment. The therapeutic effect of resiniferatoxin was significantly superior to that of placebo. References 1 : The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol2002; 168: 575. Link, Google Scholar 2 : Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J Urol2003; 170: 835. Link, Google Scholar 3 : Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry1994; 57: 169. Google Scholar 4 : Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J Urol2000; 164: 676. Link, Google Scholar 5 : Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. Eur Urol2003; 38: 444. Google Scholar 6 : Effectiveness of intravesical resiniferatoxin in treating detrusor hyperreflexia and external sphincter dyssynergia in patients with chronic spinal cord lesions. BJU Int2003; 92: 597. Google Scholar 7 : Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol1997; 158: 2093. Link, Google Scholar 8 : Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med2003; 26: 358. Google Scholar 9 : urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur Urol2005; 48: 650. Google Scholar 10 : Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJU Int2005; 95: 1023. Google Scholar 11 : Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction. Neurourol Urodyn1997; 16: 1. Google Scholar 12 : Recommendation of the International Consensus Committee concerning: 1. Prostate symptom score and quality of life assessment. Edited by . Jersey, Channel Islands: Scientific Communication International1994: 553. Proceedings: The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, June 27–30, 1993. Google Scholar 13 : Topography of the vanilloid receptor in the human bladder: more than just the nerve fibers. J Urol2002; 168: 293. Link, Google Scholar 14 : Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cell. Proc Natl Acad Sci USA2001; 98: 13396. Google Scholar 15 : Immunohistochemical evidence of vanilloid receptor 1 (VR1) in normal human bladder urothelium. Eur Urol2004; 46: 792. Google Scholar 16 : Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci2002; 5: 856. Google Scholar 17 : Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9. 5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int2004; 93: 770. Google Scholar 18 : Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Autonom Nerv Syst1990; 30: S71. Google Scholar 19 : P2X3-immunoreactive nerve fibers in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol2004; 46: 247. Google Scholar 20 : Resiniferatoxin for detrusor instability refractory to anticholinergics. Int Braz J Urol2004; 30: 53. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byChuang Y, Tyagi P, Huang C, Yoshimura N, Wu M, Kaufman J and Chancellor M (2018) Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using LiposomesJournal of Urology, VOL. 182, NO. 2, (786-792), Online publication date: 1-Aug-2009.Related articlesJournal of Urology9 Nov 2018Transient Receptor Potential Vanilloid Receptor Subtype 1 in Painful Bladder Syndrome and its Correlation With Pain Volume 176Issue 2August 2006Page: 641-645 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsurinary incontinenceadministrationintravesicalbladderresiniferatoxinbladderneurogenicMetricsAuthor Information Hann-Chorng Kuo More articles by this author Hsin-Tzu Liu More articles by this author Wen-Chin Yang Departments of Urology and Pharmacy, Buddhist Tzu Chi General Hospital and Buddhist Tzu Chi University School of Medicine, Hualien, Taiwan, Republic of China More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1999900189 created "2016-06-24" @default.
• W1999900189 creator A5027852050 @default.
• W1999900189 creator A5053694613 @default.
• W1999900189 creator A5064972271 @default.
• W1999900189 date "2006-08-01" @default.
• W1999900189 modified "2023-10-18" @default.
• W1999900189 title "Therapeutic Effect of Multiple Resiniferatoxin Intravesical Instillations in Patients With Refractory Detrusor Overactivity: A Randomized, Double-Blind, Placebo Controlled Study" @default.
• W1999900189 cites W108340196 @default.
• W1999900189 cites W1516758729 @default.
• W1999900189 cites W1971566600 @default.
• W1999900189 cites W1973361531 @default.
• W1999900189 cites W1983273712 @default.
• W1999900189 cites W1984530749 @default.
• W1999900189 cites W1988375390 @default.
• W1999900189 cites W1997629062 @default.
• W1999900189 cites W1998263996 @default.
• W1999900189 cites W2002406661 @default.
• W1999900189 cites W2009656267 @default.
• W1999900189 cites W2031151714 @default.
• W1999900189 cites W2048426485 @default.
• W1999900189 cites W2050196383 @default.
• W1999900189 cites W2084336593 @default.
• W1999900189 cites W2089363276 @default.
• W1999900189 cites W2096268332 @default.
• W1999900189 cites W2109745988 @default.
• W1999900189 cites W2114530814 @default.
• W1999900189 doi "https://doi.org/10.1016/j.juro.2006.03.087" @default.
• W1999900189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16813911" @default.
• W1999900189 hasPublicationYear "2006" @default.
• W1999900189 type Work @default.
• W1999900189 sameAs 1999900189 @default.
• W1999900189 citedByCount "45" @default.
• W1999900189 countsByYear W19999001892012 @default.
• W1999900189 countsByYear W19999001892013 @default.
• W1999900189 countsByYear W19999001892014 @default.
• W1999900189 countsByYear W19999001892015 @default.
• W1999900189 countsByYear W19999001892016 @default.
• W1999900189 countsByYear W19999001892017 @default.
• W1999900189 countsByYear W19999001892018 @default.
• W1999900189 countsByYear W19999001892020 @default.
• W1999900189 countsByYear W19999001892023 @default.
• W1999900189 crossrefType "journal-article" @default.
• W1999900189 hasAuthorship W1999900189A5027852050 @default.
• W1999900189 hasAuthorship W1999900189A5053694613 @default.
• W1999900189 hasAuthorship W1999900189A5064972271 @default.
• W1999900189 hasConcept C102652120 @default.
• W1999900189 hasConcept C121332964 @default.
• W1999900189 hasConcept C126322002 @default.
• W1999900189 hasConcept C126894567 @default.
• W1999900189 hasConcept C142424586 @default.
• W1999900189 hasConcept C142724271 @default.
• W1999900189 hasConcept C155164980 @default.
• W1999900189 hasConcept C160145004 @default.
• W1999900189 hasConcept C168563851 @default.
• W1999900189 hasConcept C170493617 @default.
• W1999900189 hasConcept C204787440 @default.
• W1999900189 hasConcept C27081682 @default.
• W1999900189 hasConcept C2776354303 @default.
• W1999900189 hasConcept C2778941218 @default.
• W1999900189 hasConcept C42219234 @default.
• W1999900189 hasConcept C71924100 @default.
• W1999900189 hasConcept C87355193 @default.
• W1999900189 hasConceptScore W1999900189C102652120 @default.
• W1999900189 hasConceptScore W1999900189C121332964 @default.
• W1999900189 hasConceptScore W1999900189C126322002 @default.
• W1999900189 hasConceptScore W1999900189C126894567 @default.
• W1999900189 hasConceptScore W1999900189C142424586 @default.
• W1999900189 hasConceptScore W1999900189C142724271 @default.
• W1999900189 hasConceptScore W1999900189C155164980 @default.
• W1999900189 hasConceptScore W1999900189C160145004 @default.
• W1999900189 hasConceptScore W1999900189C168563851 @default.
• W1999900189 hasConceptScore W1999900189C170493617 @default.
• W1999900189 hasConceptScore W1999900189C204787440 @default.
• W1999900189 hasConceptScore W1999900189C27081682 @default.
• W1999900189 hasConceptScore W1999900189C2776354303 @default.
• W1999900189 hasConceptScore W1999900189C2778941218 @default.
• W1999900189 hasConceptScore W1999900189C42219234 @default.
• W1999900189 hasConceptScore W1999900189C71924100 @default.
• W1999900189 hasConceptScore W1999900189C87355193 @default.
• W1999900189 hasIssue "2" @default.
• W1999900189 hasLocation W19999001891 @default.
• W1999900189 hasLocation W19999001892 @default.
• W1999900189 hasOpenAccess W1999900189 @default.
• W1999900189 hasPrimaryLocation W19999001891 @default.
• W1999900189 hasRelatedWork W1969863533 @default.
• W1999900189 hasRelatedWork W1986012407 @default.
• W1999900189 hasRelatedWork W2044177351 @default.
• W1999900189 hasRelatedWork W2055335617 @default.
• W1999900189 hasRelatedWork W2065590205 @default.
• W1999900189 hasRelatedWork W2087882846 @default.
• W1999900189 hasRelatedWork W2092916795 @default.
• W1999900189 hasRelatedWork W2790228640 @default.
• W1999900189 hasRelatedWork W3029548209 @default.
• W1999900189 hasRelatedWork W126388941 @default.
• W1999900189 hasVolume "176" @default.
• W1999900189 isParatext "false" @default.
• W1999900189 isRetracted "false" @default.

• next